© 1998 by European Society of Cardiology
Copyright © 1998, European Society of Cardiology
Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction
Klinik und Poliklinik für Innere Medizin II, University of Regensburg, D-93042 Regensburg, Germany
* Corresponding author. Tel.: +49-941-944-7211; Fax: +49-941-944-7213; E-mail: eckhard.kromer@klinik.uni-regensburg.de
Objectives: Growth hormone (GH) causes cardiomyocyte hypertrophy without development of fibrosis in the normal rat heart. The aim of this study was to evaluate the effects of GH on cardiac remodeling following experimental myocardial infarction (MI). Methods: Following ligation of the left coronary artery or sham operation, rats were randomized to receive 2 IU GH/kg/day or vehicle for four weeks (n=140). Extracellular matrix proteins were assessed in the non-infarcted myocardium of the posterior wall using immunohistochemistry and automatic image analysis. In addition, cardiomyocyte size was measured. Results: Compared to sham, vehicle-treated rats with moderate (20–40%) and large (>40%) infarct size showed left ventricular (LV)-dilatation, reduced fractional shortening as well as increases in LV end-diastolic and right atrial pressures, LV/body weight (BW) ratio and LV posterior wall thickness. Compared to vehicle-treated MI-rats, treatment with GH considerably increased fractional shortening and attenuated LV-dilatation. Vehicle-treated MI-rats displayed progressive increases in cardiomyocyte width and deposition of collagen I, compared to sham rats. Treatment with GH nearly doubled the increase in cardiomyocyte width and reduced collagen I accumulation by 50%. Conclusions: Our study demonstrates that GH, given early after large MI, elicits a unique pattern of structural effects characterized by enhanced cardiomyocyte hypertrophy and reduced adaptive fibrosis. This attenuation of pathological remodeling translates into a significant improvement in systolic and diastolic LV-function.
KEYWORDS Myocardial hypertrophy; Experimental myocardial infarction; Growth hormone; Cardiac function; Extracellular matrix; Fibrosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Rabkin, I. Awwad, Y. Chen, E. A. Ashley, D. Sun, S. Sood, W. Clusin, P. Heidenreich, G. Piecha, and M.-L. Gross Low-Dose Growth Hormone is Cardioprotective in Uremia J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1774 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Perez, M. R. Piaggio, I. L. Ennis, C. D. Garciarena, C. Morales, E. M. Escudero, O. H. Cingolani, G. Chiappe de Cingolani, X.-P. Yang, and H. E. Cingolani Phosphodiesterase 5A Inhibition Induces Na+/H+ Exchanger Blockade and Protection Against Myocardial Infarction Hypertension, May 1, 2007; 49(5): 1095 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marleau, M. Mulumba, D. Lamontagne, and H. Ong Cardiac and peripheral actions of growth hormone and its releasing peptides: Relevance for the treatment of cardiomyopathies Cardiovasc Res, January 1, 2006; 69(1): 26 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Komamura, R. Tatsumi, J.-i. Miyazaki, K. Matsumoto, E. Yamato, T. Nakamura, Y. Shimizu, T. Nakatani, S. Kitamura, H. Tomoike, et al. Treatment of Dilated Cardiomyopathy With Electroporation of Hepatocyte Growth Factor Gene Into Skeletal Muscle Hypertension, September 1, 2004; 44(3): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cittadini, J.o. Isgaard, M. G. Monti, C. Casaburi, A. Di Gianni, R. Serpico, G. Iaccarino, and L. Sacca Growth hormone prolongs survival in experimental postinfarction heart failure J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2154 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bollano, C.-H. Bergh, C. Kjellstrom, E. Omerovic, V. Kujacic, K. Caidahl, B.-A. Bengtsson, F. Waagstein, and J. Isgaard Growth hormone alone or combined with metoprolol preserves cardiac function after myocardial infarction in rats Eur J Heart Fail, December 1, 2001; 3(6): 651 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. de Simone, F. Pasanisi, and F. Contaldo Link of Nonhemodynamic Factors to Hemodynamic Determinants of Left Ventricular Hypertrophy Hypertension, July 1, 2001; 38(1): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Weekers, E. Van Herck, J. Isgaard, and G. Van den Berghe Pretreatment with Growth Hormone-Releasing Peptide-2 Directly Protects against the Diastolic Dysfunction of Myocardial Stunning in an Isolated, Blood-Perfused Rabbit Heart Model Endocrinology, November 1, 2000; 141(11): 3993 - 3999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.C. Wollert and H. Drexler Growth hormone and insulin-like growth factor--friends of the infarcted heart? Eur. Heart J., September 2, 2000; 21(18): 1499 - 1501. [PDF]
|
|
|
|
 |
|
 M. C. Kammerl, D. Grimm, C. Nabel, F. Schweda, M. Bach, S. Fredersdorf, H. Piehler, S. R. Holmer, G. A. J. Riegger, E. P. Kromer, et al. Effects of growth hormone on renal renin gene expression in normal rats and rats with myocardial infarction Nephrol. Dial. Transplant., June 1, 2000; 15(6): 786 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Oliviero, C. Chassagne, N. Salichon, A. Corbier, G. Hamon, F. Marotte, D. Charlemagne, L. Rappaport, and J.-L. Samuel Expression of laminin {alpha}2 chain during normal and pathological growth of myocardium in rat and human Cardiovasc Res, May 1, 2000; 46(2): 346 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fazio, A. Cittadini, B. Biondi, E. A. Palmieri, G. Riccio, F. Bonè, U. Oliviero, and L. Saccà Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 179 - 182. [Abstract] [Full Text]
|
|
|
|
|
|
J. T Beranek Does growth hormone reduce fibrosis? Cardiovasc Res, July 1, 1999; 43(1): 252 - 253. [Full Text] [PDF]
|
|
|
|
|
|
D. Grimm and E. P Kromer Growth hormone and interstitial fibrosis Cardiovasc Res, July 1, 1999; 43(1): 254 - 254. [Full Text] [PDF]
|
|